Fangfang Liu

机构：Hubei University of Medicine, Zhengzhou University, China-US (Henan) Hormel Cancer Institute, Third Affiliated Hospital of Zhengzhou University, Shenzhen Institutes of Advanced Technology, Southwest Minzu University · ORCID：0000-0003-1347-6414

发表论文 159 篇 · 总被引 2065 次 · h-index 28

代表论文

• Inflammation in cancer: therapeutic opportunities from new insights (2025 · Molecular Cancer · 被引 100)
• Dietary elaidic acid boosts tumoral antigen presentation and cancer immunity via ACSL5 (2024 · Cell Metabolism · 被引 66)
• Discovery of the potential biomarkers for early diagnosis of endometrial cancer via integrating metabolomics and transcriptomics (2024 · Computers in Biology and Medicine · 被引 16)
• Effects of different extraction solvents on the major chemical compounds and in vitro biological activities of Dendrobium chrysotoxum Lindl. stems (2024 · Industrial Crops and Products · 被引 8)
• The association of genomic alterations with PD‐L1 expression in Chinese patients with EGFR / ALK wild‐type lung adenocarcinoma and potential predictive value of Hippo pathway mutations to immunotherapy (2024 · Cancer Medicine · 被引 7)
• LncRNA MIR100HG affects the proliferation and metastasis of lung cancer cells through mediating the microRNA‐5590‐3p/DCBLD2 axis (2024 · Immunity Inflammation and Disease · 被引 6)